Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) have been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $24.25.

Several equities research analysts recently issued reports on the stock. Cantor Fitzgerald began coverage on shares of Adlai Nortye in a research report on Monday, June 22nd. They issued an “overweight” rating on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Adlai Nortye in a research report on Tuesday, July 14th. Oppenheimer started coverage on shares of Adlai Nortye in a research note on Thursday, May 28th. They set an “outperform” rating and a $32.00 price target on the stock. JonesTrading initiated coverage on shares of Adlai Nortye in a report on Thursday, May 14th. They issued a “buy” rating and a $22.00 price target on the stock. Finally, Wall Street Zen upgraded Adlai Nortye from a “hold” rating to a “buy” rating in a report on Saturday, August 22nd.

Insider Activity at Adlai Nortye

In related news, CFO Xiaofeng Ye sold 6,000 shares of the firm’s stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $13.98, for a total value of $83,880.00. Following the transaction, the chief financial officer owned 153,424 shares in the company, valued at approximately $2,144,867.52. This trade represents a 3.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Institutional Investors Weigh In On Adlai Nortye

Several institutional investors have recently bought and sold shares of the business. ADAR1 Capital Management LLC acquired a new stake in shares of Adlai Nortye in the first quarter worth $816,000. Affinity Asset Advisors LLC acquired a new position in shares of Adlai Nortye during the 1st quarter valued at $1,140,000. Boone Capital Management LLC acquired a new position in shares of Adlai Nortye during the 2nd quarter valued at $2,971,000. Braidwell LP purchased a new stake in Adlai Nortye during the 2nd quarter worth $9,145,000. Finally, Seven Fleet Capital Management LP acquired a new stake in Adlai Nortye in the 2nd quarter valued at $1,302,000. 35.21% of the stock is currently owned by hedge funds and other institutional investors.

Adlai Nortye Stock Performance

NASDAQ ANL opened at $15.01 on Friday. Adlai Nortye has a 12 month low of $0.88 and a 12 month high of $17.25. The company has a 50-day moving average of $12.55 and a 200-day moving average of $11.37. The company has a quick ratio of 0.65, a current ratio of 9.55 and a debt-to-equity ratio of 0.04.

About Adlai Nortye

Adlai Nortye Inc (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.

Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.

The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.